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Low-dose primaquine 
for falciparum malaria: 
authors’ reply 
We read with interest the 
Correspondence by Kapil Goyal and 
colleagues1 on primaquine resistance 
and Eyal Meltzer and Eli Schwartz2 
on primaquine metabolism by 
CYP2D6 in relation to our report 
on primaquine for transmission 
reduction of Plasmodium falciparum.3 
The development of resistance 
has two discrete phases: de-novo 
emergence and subsequent spread. 
Resistance arises during asexual 
reproduction and not in non-
replicating gametocytes. Although 
primaquine has been used widely for 
more than 60 years, including in mass 
drug administrations of single-dose 
formulations,4 no conclusive evidence 
exists of primaquine resistance5 in P 
falciparum gametocytes. Goyal and 
colleagues state that drug sensitivity 
assays are needed to monitor 
gametocyte resistance to primaquine 
and refer to an in-vitro screening 
system for gametocytocidal drugs.6 
This approach is unfeasible and 
uninformative for primaquine because 
the active metabolites of primaquine 
are unknown and the parent 
compound has very little activity 
in vitro.6 Moreover, the assay relies 
on a small number of gametocyte-
producing laboratory parasite isolates 
that are unlikely to represent those in 
natural infections. 
 Primaquine might exert 
a strong selective advantage to 
the small proportion of surviving 
gametocytes. Meltzer and Schwartz 
use the term failure rate for these 
surviving gametocytes, linking this to 
the slow drug metabolism by CY2D6 
in some individuals. The densities of 
surviving gametocytes were markedly 
lower than those before primaquine,3 
and the drug might further affect 
their viability.7 Further evidence of 
this finding with mosquito infectivity 
assays would allow the investigation 
of primaquine failure. We agree 
that more data are needed for the 
geographical differences in CYP2D6 
metaboliser phenotype, and we are 
establishing CYP2D6 status in our 
Ugandan cohort to inform primaquine 
policy considerations. 
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